Hexarelin
Examorelin — Hexapeptide GH Secretagogue
What is Hexarelin?
Hexarelin is the most potent GHRP available, producing the strongest GH pulse of any peptide in the class. It stimulates GH release through the ghrelin receptor (GHS-R1a) with higher affinity than other GHRPs. It also demonstrates cardioprotective properties through direct myocardial receptor binding.
Hexarelin binds GHS-R1a with higher affinity than other GHRPs, producing a larger GH pulse. Unlike the selective Ipamorelin, it also stimulates cortisol and prolactin at higher doses. Its cardioprotective effects through direct myocardial GHS-R binding are distinct from its GH-releasing mechanism.
Research Evidence
Clinical studies demonstrate Hexarelin produces significantly higher GH peaks than GHRP-2 or GHRP-6 at equivalent doses, with faster receptor desensitization.
Human studies show Hexarelin improves cardiac function in GH-deficient patients and heart failure through direct myocardial GHS-R binding — distinct from its GH-releasing action.
Community protocols report significant lean mass gains. Rapid desensitization with continuous use limits long-term application — most cycle Hexarelin with other GHRPs.
Evidence grades: Gold = RCT human data · Silver = multiple animal studies, consistent · Bronze = limited or preliminary
Dosing Protocols
Reconstitution Guide
| Vial Size | BAC Water | Concentration | Target draw |
|---|---|---|---|
| 2 mg | 2 ml | 1 mg/ml | 100mcg = 10 units |
| 5 mg | 5 ml | 1 mg/ml | 100mcg = 10 units |
Frequently Asked Questions
How does Hexarelin compare to Ipamorelin?
Hexarelin produces a stronger GH pulse but also elevates cortisol and prolactin. Ipamorelin is highly selective and does not raise cortisol or prolactin at standard doses. Ipamorelin is preferred for general GH optimization. Hexarelin is used when maximum GH stimulus or cardioprotection is the priority.
Does Hexarelin desensitize receptors?
Yes, faster than other GHRPs. Continuous daily use leads to pituitary receptor desensitization within 4-8 weeks. Cycling protocols (4 weeks on, 4 off) are standard practice.
References
- [1]Arvat E, Di Vito L, Broglio F, et al. Preliminary evidence that Hexarelin suppresses endogenous somatostatin release in humans. J Endocrinol Invest. 1997;20(7):374-380.
- [2]Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53.
This profile was prepared using AI-assisted research synthesis. Citations are provided where applicable — verify with primary sources before clinical application.
Share this article